Total amount raised
$192 Million
Latest funding date
06/01/2020
Location
Orca Bio has successfully raised funding over five rounds, with the latest being a Series F round led by Lightspeed Venture Partners. The company is backed by a total of 13 investors, including Silicon Valley Bank.
Orca Bio is focused on developing high-precision cell therapies for cancer and autoimmune diseases, leveraging regulatory T cells to improve patient outcomes. Keep reading to explore the intricacies of Orca Bio's fundraising journey and the investors backing this innovative platform.
What Is Orca Bio?
Orca Bio, based in Menlo Park, California, is a clinical-stage cell therapy company dedicated to delivering curative medicine to patients. The company operates within the health care, medical, and pharmaceutical industries and has an employee count ranging from 251 to 500.
Focused on developing high-precision cell therapies for cancer and autoimmune diseases, Orca Bio leverages regulatory T cells to improve patient outcomes. The company is committed to expanding the life-changing benefits of cell therapies, ensuring that all patients have a chance at a cure.
How Much Funding Has Orca Bio Raised?
- Series D
- Amount Raised: USD 192,000,000
- Date: June 2020
- Lead Investors: Lightspeed Venture Partners
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To develop Orca Bio's pipeline of cell therapies and its manufacturing technology, aiming to replace conventional bone marrow transplants.
- Series C
- Date: May 2018
- Investor Count: 1
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To advance clinical trials and expand research capabilities.
- Seed
- Date: May 2016
- Investor Count: 2
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To establish initial operations and begin early-stage research.
Total Amount Raised: USD 192,000,000
Current Valuation: Not publicly disclosed
Key Investors
- Lightspeed Venture Partners
- Details: Lightspeed Venture Partners is a venture capital firm that invests in the enterprise, consumer, and health sectors. They have a global presence and have backed numerous successful startups.
- Investment Focus Areas: Technology, enterprise, consumer, health sectors
- Notable Investments: Snapchat, GrubHub, Affirm
- 8VC
- Details: 8VC is a venture capital firm that focuses on technology and healthcare investments. They aim to build and support transformative companies.
- Investment Focus Areas: Technology, healthcare, logistics, financial services
- Notable Investments: Palantir, Wish, Guardant Health
- DCVC Bio
- Details: DCVC Bio is a venture capital firm specializing in deep tech and life sciences. They invest in companies that leverage computational biology and other advanced technologies.
- Investment Focus Areas: Deep tech, life sciences, computational biology
- Notable Investments: Zymergen, Recursion Pharmaceuticals, Pivot Bio
- ND Capital
- Details: ND Capital is a venture capital firm that invests in early-stage technology and life sciences companies. They focus on innovative solutions in various sectors.
- Investment Focus Areas: Life sciences, technology, sustainability
- Notable Investments: Impossible Foods, Ginkgo Bioworks, Unity Biotechnology
- Mubadala Investment Company
- Details: Mubadala Investment Company is a global investment firm based in Abu Dhabi. They manage a diverse portfolio across various sectors.
- Investment Focus Areas: Technology, healthcare, infrastructure
- Notable Investments: SoftBank Vision Fund, Cologix, Medallia
What's Next for Orca Bio?
Orca Bio stands at the forefront of a transformative opportunity in the healthcare sector. With its focus on developing high-precision cell therapies, the company aims to replace conventional bone marrow transplants, addressing significant unmet needs in treating blood cancers, autoimmune diseases, and genetic disorders. The potential to mitigate severe complications like graft-versus-host disease makes their therapies highly attractive, promising a substantial market impact.
As Orca Bio advances its clinical programs, including TRGFT-201 and OGFT-001, the company is well-positioned for future fundraising opportunities. Successful trial outcomes could attract further investment, potentially leading to additional funding rounds or strategic partnerships. The growing interest in precision medicine and cell therapies aligns with Orca Bio's mission, enhancing its appeal to investors and partners alike.
However, the path forward is not without challenges. Regulatory hurdles, clinical trial risks, and competition from other biotech firms are significant obstacles. Additionally, the high costs associated with developing and manufacturing cell therapies could pose financial strains. Despite these challenges, Orca Bio's innovative approach and strong investor backing provide a solid foundation for future growth and success.
Use Clay to Get Funding Data
Sales professionals, leverage Clay’s platform to access comprehensive fundraising data on companies like Orca Bio and gather other critical business insights. Sign up for free to start transforming your sales strategy today.
